Clinical deterioration during antitubercular treatment at a district hospital in South Africa: The importance of drug resistance and AIDS defining illnesses

PLoS ONE

Volumn 4, Issue 2, 2009, Pages

  Pepper, Dominique J ^a,b   Rebe, Kevin ^a,b   Morroni, Chelsea ^a   Wilkinson, Robert J ^a,b,c,d,e   Meintjes, Graeme ^a,b,d  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b GF Jooste Hospital   (South Africa)

^c WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

^e NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; ETHAMBUTOL; ISONIAZID; LAMIVUDINE; NEVIRAPINE; PYRAZINAMIDE; RIFAMPICIN; STAVUDINE; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETERIORATION; FEMALE; HEALTH STATUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; OUTCOME ASSESSMENT; PATIENT REFERRAL; PREVALENCE; PROGNOSIS; SOUTH AFRICA; TREATMENT DURATION; TREATMENT FAILURE; TUBERCULOSIS;

BACTERIA (MICROORGANISMS); HUMAN IMMUNODEFICIENCY VIRUS 1; MYCOBACTERIUM TUBERCULOSIS;

EID: 84887212370     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0004520     Document Type: Article

References (38)

1. WHO (2008) AIDS statistics South Africa 2007.
2. WHO (2008) TB incidence South Africa 2006.
3. Sonnenberg P, Glynn JR, Fielding K, Murray J, Godfrey-Faussett P, et al. (2005) How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis 191: 150-158.
4. Wood R, Maartens G, Lombard CJ (2000) Risk factors for developing tuberculosis in HIV-1 infected adults from communities with a low or very high incidence of tuberculosis. JAIDS Journal of Acquired Immune Deficiency Syndromes 23: 75-80.
5. Collins KR, Quinones-Mateu ME, Toossi Z, Arts EJ (2002) Impact of tuberculosis on HIV-1 replication, diversity, and disease progression. AIDS Rev 4: 165-176.
6. Lawn SD, Pisell TL, Hirsch CS, Wu M, Butera ST, et al. (2001) Anatomically compartmentalized human immunodeficiency virus replication in HLA-DR+ cells and CD14+ macrophages at the site of pleural tuberculosis coinfection. J Infect Dis 184: 1127-1133.
7. Toossi Z, Johnson JL, Kanost RA, Wu M, Luzze H, et al. (2001) Increased replication of HIV-1 at sites of Mycobacterium tuberculosis infection: potential mechanisms of viral activation. J Acquir Immune Defic Syndr 28: 1-8.
8. WHO (2007) WHO REPORT 2007 GLOBAL TUBERCULOSIS CONTROL. http://wwwwhoint/ tb/publications/global_report/2007/pdf/zafpdf.
9. WHO (2005) Key TB and TB/HIV facts and figures (World TB Day 2005) http://wwwwhoint/3by5/en/factspdf: Accessed 29 January 2008.
10. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, et al. (2006) Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. The Lancet 368: 1575-1580.
11. Maartens G, Wilkinson RJ (2007) Tuberculosis. Lancet 370: 2030-2043.
12. Greenberg AE, Lucas S, Tossou O, Coulibaly IM, Coulibaly D, et al. (1995) Autopsy-proven causes of death in HIV-infected patients treated for tuberculosis in Abidjan, Cote d'Ivoire. AIDS 9: 1251-1254.
13. Ansari NA, Kombe AH, Kenyon TA, Hone NM, Tappero JW, et al. (2002) Pathology and causes of death in a group of 128 predominantly HIV-positive patients in Botswana, 1997-1998. Int J Tuberc Lung Dis 6: 55-63.
14. Eza D, Cerrillo G, Moore DAJ, Castro C, Ticona E, et al. (2006) Postmortem findings and opportunistic infections in HIV-positive patients from a public hospital in Peru. Pathology-Research and Practice 202: 767-775.
15. Martinson N, Hale M, Karstaedt A (2007) Causes of Death in HIV-infected Adults with TB Admitted to 2 Hospitals in Soweto, South Africa. Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections.
16. Small PM, Shafer RW, Hopewell PC, Singh SP, Murphy MJ, et al. (1993) Exogenous Reinfection with Multidrug-Resistant Mycobacterium tuberculosis in Patients with Advanced HIV Infection. New England Journal of Medicine 328: 1137.
17. Narita M, Ashkin D, Hollender ES, Pitchenik AE (1998) Paradoxical Worsening of Tuberculosis Following Antiretroviral Therapy in Patients with AIDS. American Journal of Respiratory and Critical Care Medicine 158: 157-161.
18. Lawn SD, Bekker LG, Miller RF (2005) Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. The Lancet Infectious Diseases 5: 361-373.
19. McIlleron H, Meintjes G, Burman WJ, Maartens G (2007) Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis 196 Suppl 1: S63-75.
20. Pepper DJ, Meintjes GA, McIlleron H, Wilkinson RJ (2007) Combined therapy for tuberculosis and HIV-1: the challenge for drug discovery. Drug Discovery Today 12: 980-989.
21. Hoffmann CJ, Charalambous S, Thio CL, Martin DJ, Pemba L, et al. (2007) Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS 21: 1301-1308.
22. Kwara A, Flanigan TP, Carter EJ (2005) Highly active antiretroviral therapy (HAART) in adults with tuberculosis: current status. International Journal of Tuberculosis and Lung Disease 9: 248-257.
23. Brudney K, Dobkin J (1992) Resurgent Tuberculosis in New York City: Human Immunodeficiency Virus, Homelessness, and the Decline of Tuberculosis Control Programs. Journal of Public Health Policy 13: 435-450.
24. Rao SN, Mookerjee AL, Obasanjo OO, Chaisson RE (2000) Errors in the Treatment of Tuberculosis in Baltimore*. Am Coll Chest Phys. pp 734-737.
25. Burch VC, Benatar SR (2006) Rational planning for health care based on observed needs. S Afr Med J 96: 796-802.
26. SATBguidelines (2004) South African National Tuberculosis Control Programme Practical guidelines. http://wwwecdohgovza/uploads/files/ 150906152233pdf.
27. Barnard M, Albert H, Coetzee G, O'Brien R, Bosman ME (2008) Rapid Molecular Screening for MDR TB in a High Volume Public Health Laboratory in South Africa. Am J Respir Crit Care Med.
28. WHO (2007) The Global MDR-TB & XDR-TB Response Plan 2007-2008 http://whqlibdocwhoint/hq/2007/WHO_HTM_TB_2007387_engpdf.
29. Meintjes G, Lawn SD, Scano F, Maartens G, French MA, et al. (2008) Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 8: 516-523.
30. Weyer K (2007) Case study: South Africa. Bull World Health Organ 85.
31. Niemann S, Richter E, Rusch-Gerdes S, Schlaak M, Greinert U (2000) Double infection with a resistant and a multidrug-resistant strain of Mycobacterium tuberculosis. Emerg Infect Dis 6: 548-551.
32. Borges AS, Ferreira MS, Nishioka SA, Silvestre MTA, Silva AM, et al. (1997) Agreement between premortem and postmortem diagnoses in patients with acquired immunodeficiency syndrome observed at a brazilian teaching hospital. Revista do Instituto de Medicina Tropical de Saão Paulo 39: 217-222.
33. TB/HIVPolicy (2004) TB/HIV Policy Task Group Tuberculosis & HIV and AIDS - Clinical Guidelines -. http://wwwdohgovza/aids/docs/ tuberculosishtml#adults.
34. Breton G, Duval X, Estellat C, Poaletti X, Bonnet D, et al. (2004) Determinants of Immune Reconstitution Inflammatory Syndrome in HIV Type 1-Infected Patients with Tuberculosis after Initiation of Antiretroviral Therapy. Clinical Infectious Diseases 39: 1709-1712.
35. Shelburne SA, Montes M, Hamill RJ (2006) Immune reconstitution inflammatory syndrome: more answers, more questions. Br Soc Antimicrob Chemo. pp 167-170.
36. Dhasmana DJ, Dheda K, Ravn P, Wilkinson RJ, Meintjes G (2008) Immune reconstitution inflammatory syndrome in HIV-infected patients receiving antiretroviral therapy: pathogenesis, clinical manifestations and management. Drugs 68: 191-208.
37. White NW (1989) Venous thrombosis and rifampicin. Lancet 2: 434-435.
38. Matta F, Yaekoub AY, Stein PD (2008) Human immunodeficiency virus infection and risk of venous thromboembolism. Am J Med Sci 336: 402-406.